Ir al contenido principal

Dermatitis herpetiforme

Profesionales Médicos

Los artículos de Referencia Profesional están diseñados para ser utilizados por profesionales de la salud. Están escritos por médicos del Reino Unido y se basan en evidencia de investigación, así como en guías del Reino Unido y Europa. Puede encontrar el Dermatitis herpetiforme artículo más útil, o uno de nuestros otros artículos de salud.

Continúa leyendo abajo

¿Qué es la dermatitis herpetiforme?

Dermatitis herpetiformis (DH) is an autoimmune blistering skin disease associated with coeliac disease (gluten enteropathy). DH may be considered as a cutaneous manifestation of coeliac disease.

  • For coeliac disease, UK prevalence is around 1%.

  • However, dermatitis herpetiformis is far more uncommon, affecting between 11.5 and 75 per 100,000.

  • The most common age of onset is between the third and fourth decade, although the condition may occur at any age after weaning.2

  • Male patients are affected twice as often as female patients.

  • Dermatitis herpetiformis predominately affects people of Northern European descent.

  • Many cases are still under-diagnosed. Diagnosis is challenging, and is frequently delayed by months to years.

  • The incidence of dermatitis herpetiformis is decreasing, whereas the incidence of coeliac disease is increasing; this may reflect greater awareness and earlier diagnosis of coeliac disease (including via increased use of serological screening), leading to less time for dermatitis herpetiformis to develop.3

Continúa leyendo abajo

  • Although about 80% of those with dermatitis herpetiformis show histopathological changes of coeliac disease on small intestinal biopsy, only 20% of these patients initially have symptoms of coeliac disease.4

  • Around 17% of patients with coeliac disease have DH.5

  • DH may be the first presentation of coeliac disease is some cases.

  • As in coeliac disease, the core pathogenic mechanisms of DH are thought to be mediated by immunoglobulin A class autoantibodies against one of several transglutaminase enzymes.6

  • Around 10% of patients have other autoimmune conditions, particularly autoimmune thyroid diseases, pernicious anaemia, gastric atrophy, type I diabetes, lupus eritematoso sistémico, Síndrome de Sjögren, sarcoidosis, vitiligo y alopecia areata.

Dermatitis herpetiformis is an intensely itchy bullous rash characterised clinically by grouped vesicles on an erythematous base. It characteristically affects extensor surfaces, particularly the scalp, buttocks, elbows and knees. However, lesions can occur on any area of skin.

  • The lesions are papules and blisters, up to 1 cm in diameter, which are extremely itchy. They arise on normal or reddened skin. Burning, stinging and intense pruritus can precede the appearance of new lesions.

  • Lesions tend to grow in a centrifugal pattern, with vesicles predominating in the periphery.

  • The severity can vary from week to week.

  • Lesions rarely resolve without specific treatment.

  • NB: primary lesions often are absent owing to the intense, associated pruritus. Instead, many cases present only with erythematous erosions with numerous overlying excoriations.6

Erupción de dermatitis herpetiforme

Dermatitis herpetiforme

There may also be symptoms of enfermedad celíaca.

Continúa leyendo abajo

Biopsia de piel

The major diagnostic criterion for diagnosis is the presence of granular IgA deposits in the dermal papillae of uninvolved perilesional skin as shown by direct immunofluorescence, and the diagnosis should not be made unless this has been confirmed.2

Testing for coeliac disease

  • Diagnosis of coeliac disease is by serology and duodenal biopsy, ideally with the patient on a normal - that is, gluten-containing - diet.

  • IgA anti-tissue transglutaminase or IgA endomysial antibodies are highly specific and sensitive for untreated coeliac disease.4 They are also relevant to dermatitis herpetiformis patients.

  • Because of their low sensitivity and specificity, antigliadin antibodies are no longer recommended for initial testing.

  • Biopsy remains essential for the diagnosis of adult coeliac disease and cannot be replaced by serology.2

Other possible investigations

  • If serology supports the diagnosis of coeliac disease, useful additional blood tests, including FBC, a blood film, haematinics (vitamin B12, folate, ferritin) and U&Es may highlight deficiencies secondary to intestinal malabsorption.7

  • TFTs are also necessary because of the association of thyroid disease with both coeliac disease and dermatitis herpetiformis.

  • Investigations for other autoimmune diseases are often necessary.

The presence of plaques (psoriasis), interdigital burrows (scabies), or mucosal blistering (pemphigus) usually suggest an alternative diagnosis.7

A strict gluten-free diet

This is important in order to:

  • Reduce the medication needed to control skin symptoms. It may be possible to discontinue dapsone when on a gluten-free diet for sufficient time.

  • Reduce the associated enteropathy, and improve nutrition and bone density.

Tratamiento farmacológico

  • Dapsone is first choice in cases refractory to dietary management alone and reduces the itch within a day or two.6

  • Dapsone does not have any effect on intestinal disease.8

  • Patients taking dapsone should be counselled about the risks associated with dapsone, which include haemolytic anaemia, agranulocytosis, methaemoglobinaemia, and peripheral neuropathy.7 Regular FBCs are necessary.

  • Sulfapyridine is usually used as an alternative for those cases that do not improve with dapsone.

Complications may arise from problems associated with coeliac disease. These include:

  • Neurological problems - ataxia (gluten ataxia), peripheral neuropathy, and epilepsy.

  • Cardiac problems - pericarditis and cardiomyopathy.

  • Osteoporosis and poor dental enamel.9

  • Aphthous ulcers.

  • Dermatitis herpetiformis shares with coeliac disease an increased risk of developing lymphomas but this seems to be confined to those with severe gut involvement. The risk similarly declines with time on a strict gluten-free diet.2

  • Untreated, dermatitis herpetiformis follows a prolonged course over years, with relapses and remissions.

  • The prognosis is good, as dermatitis herpetiformis responds well to diet and medication:

    • About 80% of patients with dermatitis herpetiformis have good results from a gluten-free diet. The recovery rate varies and some patients can take up to four years to respond.

    • More than 70% of patients on a strict gluten-free diet are able to slowly wean off dapsone slowly over a period of 24 months.2

Actualizaciones exclusivas para profesionales de la salud

Mantente informado con las últimas actualizaciones clínicas, perspectivas profesionales y orientación basada en evidencia. El boletín de Patient Pro selecciona contenido esencial para profesionales de la salud, entregado directamente en tu bandeja de entrada.

Por favor, introduce una dirección de correo electrónico válida

Al suscribirte aceptas nuestros Política de Privacidad. Puedes darte de baja en cualquier momento. Nunca vendemos tus datos.

Lecturas adicionales y referencias

  1. Plotnikova N, Miller JL; Dermatitis herpetiformis. Skin Therapy Lett. 2013 Mar-Apr;18(3):1-3.
  2. Ludvigsson JF, Bai JC, Biagi F, et al; Diagnóstico y manejo de la enfermedad celíaca en adultos: directrices de la Sociedad Británica de Gastroenterología. Gut. 2014 Ago;63(8):1210-28. doi: 10.1136/gutjnl-2013-306578. Publicado en línea el 10 de junio de 2014.
  3. Reunala T, Hervonen K, Salmi T; Dermatitis Herpetiforme: Una actualización sobre diagnóstico y manejo. Am J Clin Dermatol. 2021 May;22(3):329-338. doi: 10.1007/s40257-020-00584-2.
  4. Pelkowski TD, Viera AJ; Celiac disease: diagnosis and management. Am Fam Physician. 2014 Jan 15;89(2):99-105.
  5. Salmi TT, Hervonen K, Kurppa K, et al; Celiac disease evolving into dermatitis herpetiformis in patients adhering to normal or gluten-free diet. Scand J Gastroenterol. 2015 Apr;50(4):387-92. doi: 10.3109/00365521.2014.974204. Epub 2015 Feb 1.
  6. Yost JM, Hale CS, Meehan SA, et al; Dermatitis herpetiformis. Dermatol Online J. 2014 Dec 16;20(12). pii: 13030/qt4kg43857.
  7. Jakes AD, Bradley S, Donlevy L; Dermatitis herpetiformis. BMJ. 2014 Apr 16;348:g2557. doi: 10.1136/bmj.g2557.
  8. Clarindo MV, Possebon AT, Soligo EM, et al; Dermatitis herpetiformis: pathophysiology, clinical presentation, diagnosis and treatment. An Bras Dermatol. 2014 Nov-Dec;89(6):865-75; quiz 876-7.
  9. Lorinczy K, Juhasz M, Csontos A, et al; Does dermatitis herpetiformis result in bone loss as coeliac disease does? A cross sectional study. Rev Esp Enferm Dig. 2013 Apr;105(4):187-193.

Continúa leyendo abajo

Sobre el autorVer biografía completa

Imagen del autor

Dr Doug McKechnie, MRCGP

Redactor Médico

MA, MBBS, MSc, DRCOG, MRCP(UK), MRCGP(2021), FHEA

El Dr. Doug McKechnie es un médico de cabecera del NHS que trabaja en Londres. Trabaja a tiempo completo en la práctica clínica y también es el Subdirector del módulo de Práctica Clínica y Profesional en la Escuela de Medicina del University College London.

Acerca del revisorVer biografía completa

Imagen del autor

Dr Krishna Vakharia, MRCGP

Director Médico de Salud, Optum UK

MBChB, MRCGP(2013), BMedSci (hons), DFSRH, DRCOG, PGDipDerm (Distn)

La Dra. Krishna Vakharia es una médica general del NHS. También es examinadora habitual del Diploma de Posgrado en Dermatología Práctica en la Universidad de Cardiff, además de ser la Directora Médica de salud en Optum UK.

Historial del artículo

La información en esta página está escrita y revisada por pares por clínicos calificados.

verificador de elegibilidad para la gripe

Pregunta, comparte, conecta.

Navega por discusiones, haz preguntas y comparte experiencias en cientos de temas de salud.

verificador de síntomas

¿Te sientes mal?

Evalúa tus síntomas en línea de forma gratuita